X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PROCTER & GAMBLE HEALTH GLENMARK PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 12.5 57.5 21.8% View Chart
P/BV x 2.2 10.0 22.4% View Chart
Dividend Yield % 0.5 0.3 138.3%  

Financials

 GLENMARK PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
PROCTER & GAMBLE HEALTH
Dec-17
GLENMARK PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs9301,358 68.5%   
Low Rs517933 55.5%   
Sales per share (Unadj.) Rs322.6665.0 48.5%  
Earnings per share (Unadj.) Rs28.556.6 50.4%  
Cash flow per share (Unadj.) Rs39.272.5 54.1%  
Dividends per share (Unadj.) Rs2.0015.00 13.3%  
Dividend yield (eoy) %0.31.3 21.1%  
Book value per share (Unadj.) Rs183.0441.7 41.4%  
Shares outstanding (eoy) m282.1716.60 1,699.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.7 130.3%   
Avg P/E ratio x25.420.2 125.5%  
P/CF ratio (eoy) x18.515.8 116.9%  
Price / Book Value ratio x4.02.6 152.5%  
Dividend payout %7.026.5 26.5%   
Avg Mkt Cap Rs m204,20619,011 1,074.1%   
No. of employees `00013.71.5 888.3%   
Total wages/salary Rs m18,7181,696 1,103.4%   
Avg. sales/employee Rs Th6,636.87,150.0 92.8%   
Avg. wages/employee Rs Th1,364.71,098.7 124.2%   
Avg. net profit/employee Rs Th586.1608.2 96.4%   
INCOME DATA
Net Sales Rs m91,03111,040 824.6%  
Other income Rs m914240 381.3%   
Total revenues Rs m91,94511,279 815.2%   
Gross profit Rs m16,1541,376 1,173.8%  
Depreciation Rs m3,019264 1,143.5%   
Interest Rs m2,8560-   
Profit before tax Rs m11,1931,352 828.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m3,155583 541.3%   
Profit after tax Rs m8,039939 856.0%  
Gross profit margin %17.712.5 142.4%  
Effective tax rate %28.243.1 65.4%   
Net profit margin %8.88.5 103.8%  
BALANCE SHEET DATA
Current assets Rs m69,8877,523 928.9%   
Current liabilities Rs m32,8792,253 1,459.6%   
Net working cap to sales %40.747.7 85.2%  
Current ratio x2.13.3 63.6%  
Inventory Days Days8152 156.1%  
Debtors Days Days9341 230.5%  
Net fixed assets Rs m28,8921,240 2,330.5%   
Share capital Rs m282166 170.0%   
"Free" reserves Rs m51,3537,167 716.6%   
Net worth Rs m51,6357,333 704.2%   
Long term debt Rs m41,4180-   
Total assets Rs m125,9549,912 1,270.7%  
Interest coverage x4.9NM-  
Debt to equity ratio x0.80-  
Sales to assets ratio x0.71.1 64.9%   
Return on assets %8.69.5 91.3%  
Return on equity %15.612.8 121.6%  
Return on capital %15.120.8 72.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,3171,015 3,579.5%   
Fx outflow Rs m9,7203,043 319.4%   
Net fx Rs m26,598-2,028 -1,311.5%   
CASH FLOW
From Operations Rs m16,481537 3,071.3%  
From Investments Rs m-10,133-476 2,127.5%  
From Financial Activity Rs m-4,685-220 2,131.5%  
Net Cashflow Rs m1,770-160 -1,109.7%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 6.9 18.2 37.9%  
FIIs % 34.4 1.0 3,440.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 29.1 36.1%  
Shareholders   56,727 28,591 198.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   CIPLA  PFIZER  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 305 Points Lower; FMCG and Finance Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.

Related Views on News

REPCO HOME Plunges by 5%; BSE 500 Index Down 0.6% (Market Updates)

Jul 22, 2019 | Updated on Jul 22, 2019

REPCO HOME share price has plunged by 5% and its current market price is Rs 354. The BSE 500 is down by 0.6%. The top gainers in the BSE 500 Index are YES BANK (up 9.8%) and DISH TV (up 7.9%). The top losers are REPCO HOME (down 5.2%) and PROCTER & GAMBLE HEALTH (down 5.3%).

BAJAJ FINSERV Plunges by 5%; BSE 500 Index Down 0.7% (Market Updates)

Jul 22, 2019 | Updated on Jul 22, 2019

BAJAJ FINSERV share price has plunged by 5% and its current market price is Rs 7,556. The BSE 500 is down by 0.7%. The top gainers in the BSE 500 Index are YES BANK (up 7.7%) and SUN PHARMA ADV. RES. (up 4.8%). The top losers are BAJAJ FINSERV (down 5.3%) and PROCTER & GAMBLE HEALTH (down 5.2%).

PROCTER & GAMBLE HEALTH Plunges by 5%; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Jul 22, 2019 | Updated on Jul 22, 2019

PROCTER & GAMBLE HEALTH share price has plunged by 5% and its current market price is Rs 4,618. The BSE HEALTHCARE is up by 0.6%. The top gainers in the BSE HEALTHCARE Index are SUN PHARMA ADV. RES. (up 5.1%) and SUN PHARMA (up 4.1%). The top losers is PROCTER & GAMBLE HEALTH (down 5.4%)..

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 22, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ELDER PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS